Medtronic stock climbed 5.1% in morning trading after the medical device company released its fiscal fourth-quarter results before the opening bell. The quarter produced $9.8 billion in revenue, a 9.9% increase as reported and a 6.6% gain on an organic basis. Revenue outperformed the company's own implied guidance by 90 basis points. Non-GAAP diluted earnings per share for the quarter were $1.55, also ahead of guidance.
For the full fiscal year 2026, Medtronic reported worldwide revenue of $36.4 billion, representing an 8.4% rise as reported and a 5.8% increase organically. Management noted this figure as the company’s strongest annual revenue growth in ten years.
A major contributor to the better-than-expected results was the Cardiac Ablation Solutions segment, which expanded 78% in the quarter overall and surged 124% in the U.S. Management said the business is now annualizing at more than $2 billion in revenue, making it a standout driver of the company’s top-line momentum.
In addition to the operating results, Medtronic’s board approved a quarterly dividend increase to $0.72 per ordinary share, equivalent to $2.88 on an annualized basis. The increase represents the company’s 49th consecutive year of dividend growth. CEO Geoff Martha commented on the quarter, stating: "These results represent the compounding impact of deliberate choices we’ve made across strategy, operations, and culture."
Despite the upbeat set of results and the dividend action, Medtronic’s guidance for fiscal 2027 adjusted EPS landed below analyst consensus. The company projected adjusted EPS of $5.90 to $6.00, compared with a consensus of $6.06. That gap tempered some of the initial market enthusiasm following the report.
Even so, investors appeared to favor other elements of management’s outlook. Medtronic provided guidance for fiscal 2027 organic revenue growth of 6.75% to 7.25%, and the firm’s record annual revenue gain combined with the strong performance in high-growth areas helped sustain the rally through the morning session.
The movement in Medtronic shares was driven by company-specific developments rather than broad market support. During the same trading session, the S&P 500 declined 0.3%, the Dow Jones Industrial Average fell 0.5%, and the NASDAQ slid 0.5%. That placed the stock’s advance squarely in the context of internal results and outlook rather than an overall market lift.
Market observers also noted the competitive landscape. Key competitor Intuitive Surgical continues to develop around its established robotic surgery platform, but Medtronic’s robust cardiac and surgical performance appeared to reassure investors about the company’s standing in the medical device sector.
In sum, a combination of a decisive quarterly earnings beat, the most substantial annual revenue growth in a decade, a dividend increase, and rapid expansion in Cardiac Ablation Solutions supported a notable intraday gain for Medtronic. Those positives largely offset the disappointment among some investors about the company’s fiscal 2027 adjusted EPS range, as management’s revenue-growth guidance and segment momentum underpinned confidence in the business trajectory.